Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the TheraVance BioPharma Second Quarter 2025 Conference Call. During the presentation, all participants will be in a listen-only mode. The question and answer session will follow the company's formal remarks. To ask a question, press star 1-1 on your telephone. If listening via webcast, please mute audio on your webcast device before asking a question over the phone. I will repeat these instructions after management completes their prepared remarks. Also, today's conference is being recorded. And now I would like to turn the call over to Rick Winningham, Chief Executive Officer. Please go ahead, sir. Good afternoon, and welcome to TheraVance BioPharma's Second Quarter 2025 Earnings Results Conference Call. On slide 2, you'll find our forward-looking statements disclaimer, which covers certain risk factors which could cause actual results to differ materially from any such statements we might make in today's call, and which are described further in our filings with the SEC. Moving to slide 3, I'm joined today by Rhonda Farnham, Chief Business Officer, Anya Miller, Head of Development, and Aziz Salah, Chief Financial Officer. And turning to slide 4, we delivered an excellent quarter underscored by disciplined execution across our commercial and development organizations, which drove continued momentum in both UPELRI and Amperloxetine. In addition, we completed a high-impact strategic transaction. This performance reflects a team that sharply focused on delivering value to our stakeholders. Starting with our commercial business, UPELRI, our durable cash-generating product, continues to perform. Net sales for the quarter reached approximately $66 million, driven by continued demand growth and favorable...